H.C. Wainwright lowered the firm’s price target on Axsome Therapeutics (AXSM) to $180 from $200 and keeps a Buy rating on the shares. The company reported a revenue and earnings miss in Q1, the analyst tells investors in a research note. The firm cites Axsome’s moderately slower revenue ramp for the target cut.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Strong Buy Rating for Axsome Therapeutics Driven by Product Performance and Pipeline Progress
- Axsome Therapeutics price target raised to $176 from $174 at BofA
- Axsome Therapeutics price target raised to $162 from $160 at Baird
- Axsome Therapeutics price target raised to $165 from $160 at Wells Fargo
- Axsome Therapeutics: Strong Market Performance and Promising Growth Potential with Key Catalysts Ahead